Funding & VC

GenSight raises €1.1 million ahead of RECOVER Phase 3

GenSight Biologics raised €1.1 million, generating about €1.05 million net, to fund operations through late March 2027 and prepare structural financing for RECOVER Phase 3.

By Amara Osei

3 min read

GenSight Biologics Raises €1.1 Million To Support Operations And Phase 3 Preparations
GenSight Biologics Raises €1.1 Million To Support Operations And Phase 3 PreparationsBelova59 / pixabay

By Amara Osei

GenSight Biologics raised €1.1 million in financing that generated approximately €1.05 million in net proceeds, the company said. It will direct the capital to operations and working capital while preparing structural financing for the RECOVER Phase 3 trial.

GenSight expects the money to support operations through late March 2027. That timetable depends partly on the number of patients receiving treatment through its French early-access program, so treatment volume will influence how far the proceeds carry the company.

What does the financing cover?

GenSight said the transaction supplements its October 2026 fundraising and addresses a previously disclosed near-term requirement of up to €2 million. Beyond liquidity, the company is preparing for regulatory discussions and seeking longer-term financing for the next stage of development.

Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics, said:

With this financing, we have completed, on schedule, the approximately €2 million raise we announced with our half-year results. We are grateful to Invus and Heights, who have been among our most consistent supporters since November 2024, for standing alongside GenSight once again.

Their renewed commitment allows us to approach our upcoming interactions with regulatory agencies with confidence, while we continue to make GS010/LUMEVOQ available to patients through early access and prepare a structural financing for the next phase of its development.

GenSight described the new money as support for operations while it prepares structural financing, not as the final capital package for RECOVER Phase 3. The company said it continues to seek longer-term financing for the trial’s next development stage. Regulatory preparation runs alongside that fundraising effort.

What are the deal terms?

GenSight disclosed three components in the financing:

  • Approximately 4.2 million ordinary shares
  • 13.2 million pre-funded warrants
  • 17.4 million investor warrants

Full exercise of the warrants could produce an additional €925,669 in gross proceeds, GenSight said. That potential amount depends on exercise and sits outside the approximately €1.05 million in net proceeds already generated.

Because the additional cash is contingent, GenSight’s immediate liquidity remains anchored to the current net proceeds. The disclosed package combines issued equity with two warrant classes that could expand the financing if exercised.

What is GenSight developing?

GenSight develops gene therapies for retinal neurodegenerative diseases and central nervous system disorders, according to the company. Its current work includes GS010, also known as LUMEVOQ.

The company said GS010/LUMEVOQ remains available to certain patients through early-access programs. The French program also adds treatment volume to the calculation of how long GenSight’s operating proceeds will last.

How does the funding sequence work?

GenSight’s October 2026 fundraising and the new transaction address the near-term requirement of up to €2 million previously disclosed by the company. Umiastowski said the broader approximately €2 million raise announced with GenSight’s half-year results was completed on schedule.

The transaction covers immediate operating and working-capital needs, while structural financing for RECOVER Phase 3 remains the next fundraising objective, GenSight said. The company is also preparing for upcoming regulatory interactions. Both efforts must advance before the current proceeds reach their expected operating limit.

GenSight’s runway remains conditional rather than fixed. The company said treatment levels through the French early-access program will partly determine how long the financing supports operations through late March 2027. The forecast therefore depends on a clinical-access variable as well as the company’s ability to raise more capital.

GenSight’s next test is whether it can secure structural financing for RECOVER Phase 3 before the expected late-March 2027 operating window closes. French early-access treatment levels and regulatory preparation will shape the company’s path to that financing.

Source: pulse2.com

Share this article:

More from Amara Osei

Amara Osei

Show full bio

Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.

2,503 articles

Related articles

« Previous article